<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871585</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OHR-CAS-2008/1</org_study_id>
    <nct_id>NCT00871585</nct_id>
  </id_info>
  <brief_title>Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide</brief_title>
  <official_title>Non-interventional Observational Study to Evaluate Change of PSA Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide in Combination With Medical or Surgical Castration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-comparative, non-interventional, observational study to collect and analyse
      real life environment data on advanced prostate cancer patients receiving combination
      treatment of medical or surgical castration and bicalutamide according to routine medical
      practice in Croatia. The main aim is to evaluate change of PSA level and prescribing
      practices based on prostate cancer stage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate change in PSA level following 4-9 months of bicalutamide therapy</measure>
    <time_frame>PSA - 2 measures (at the time of bicalutamdie introduction and 4-9 m following bicalutamide)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bicalutamide prescribing practice based on prostate cancer stage</measure>
    <time_frame>1 measure (at the time of bicalutamde th introduction)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate PSA level after 4-12 weeks of bicalutamide therapy</measure>
    <time_frame>PSA - 1 measures (1-3 m following bicalutamide)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to asses time to disease progression based on PSA values</measure>
    <time_frame>PSA - 3 measures (at the time of bicalutamdie introduction, 1-3 m and 4-9 m following bicalutamide)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate percentage of patients with disease progression</measure>
    <time_frame>2 measures at 1st and 2nd visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate withdrawals due to adverse events</measure>
    <time_frame>2 measures, at 1st and 2nd visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate withdrawals due to Croatian Institute for Health Insurance guidelines for bicalutamide prescription</measure>
    <time_frame>2 measures, at 1st and 2nd visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">340</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        400 advanced prostate cancer patients (outpatients or hospitalized) treated with
        bicalutamide in combination with medical or surgical castration according to standard
        clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of advanced prostate cancer

          -  Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12
             weeks

          -  Patients capable of signing ICF

        Exclusion Criteria:

          -  Patients with hypersensitivity to bicalutamide

          -  Patients on therapy with terfenadin, astemizol or cisapride

          -  Participation in a clinical study during the last 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Marija Gjurovic</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreja Hasenohrl</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cakovec</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dubrovnik</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pula</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sibenik</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slavonski brod</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinkovci</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Virovitica</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vukovar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabok</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zadar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ana Marija Gjurovic, Medical&amp;Regulatory Manager</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>bicalutamide</keyword>
  <keyword>PSA</keyword>
  <keyword>advanced prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

